WO1997036632A1 - Catheter et procede pour provoquer une tension le long de l'axe du catheter - Google Patents

Catheter et procede pour provoquer une tension le long de l'axe du catheter Download PDF

Info

Publication number
WO1997036632A1
WO1997036632A1 PCT/US1997/004614 US9704614W WO9736632A1 WO 1997036632 A1 WO1997036632 A1 WO 1997036632A1 US 9704614 W US9704614 W US 9704614W WO 9736632 A1 WO9736632 A1 WO 9736632A1
Authority
WO
WIPO (PCT)
Prior art keywords
proximal
catheter
distal
balloon
urethra
Prior art date
Application number
PCT/US1997/004614
Other languages
English (en)
Inventor
Keith R. Hildebrand
James S. Sharrow
Original Assignee
Iotek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iotek, Inc. filed Critical Iotek, Inc.
Publication of WO1997036632A1 publication Critical patent/WO1997036632A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape

Definitions

  • the present invention relates to catheters, and more specifically to a catheter that is configured to generate axial tension between multiple occlusion balloons.
  • the urethra includes the prostatic urethra, the membranous urethra, bulbous urethra, and the pendulous urethra. All of the major ducts of the prostate gland open on the surface of the prostatic urethra. These ducts extend into the prostate and branch into ductules (smaller ducts) and eventually end in acini (rounded sacs). The outside of the prostate gland is surrounded by a tough fibrous capsule that serves as a substantial physical barrier between the spongy prostatic tissue and the rest of the peritoneal environment. By using an appropriately designed catheter that is introduced through the urethra, it is possible to access the prostate gland via the prostatic ducts that extend deep into the gland.
  • devices configured to deliver fluids to the prostate gland via the prostatic urethra that have a delivery balloon made from a porous membrane.
  • the delivery balloon is placed into the prostatic urethra and inflated with a fluid.
  • the fluid is pressurized so that it is caused to pass through the porous or perforated membrane and transported into the prostatic ducts.
  • the pressurized balloon expands and exerts a force against the walls of the prostatic urethra. This force compresses the prostatic tissue and causes the ducts to restrict and block the flow of the fluid into the prostate gland.
  • the fluid typically does not distribute evenly throughout the ducts, nor throughout the prostate gland. Compression of the prostatic ducts also prevents or slows the flow of the fluid into the interior of the prostate gland.
  • Another impediment is the porous membrane through which the fluid must pass before it enters the prostatic ducts. Such an impediment slows the flow of the fluid and results in additional inefficiency. Slowing the flow of the fluid results in longer delivery times and most likely lower levels of drug in the prostate gland. Additionally, a longer administration period requires additional time from the caregiver. This expense is passed on to the patient, thereby increasing the cost of treatment.
  • catheters that include multiple occlusion balloons.
  • these catheters rely on only inflation pressure within the balloons in order to create a seal between the balloon and the wall of a passageway.
  • Such devices have a significant problem because the balloon pressure alone is not always adequate to prevent a fluid from seeping between the balloon and the passageway wall during high pressure delivery. Therefore, there is also a need for a catheter that is capable of enhancing the sealing effect of occlusion balloons on a catheter.
  • the present invention is directed to an apparatus for delivering fluid to a treatment area of a patient.
  • the apparatus comprises a catheter having first and second portions.
  • the second portion is more elastic than the first portion.
  • Distal and proximal balloons are operably connected to the catheter.
  • the distal and proximal balloons are positioned so that at least a part of the second portion of the catheter is located between the distal and proximal balloons.
  • Another embodiment of the present invention is a method of delivering an agent to the prostate gland of a patient having a urethra and bladder.
  • the method utilizes a catheter having proximal and distal balloons and an intermediate portion between the proximal and distal balloons.
  • the method comprises the steps of inserting the catheter through the urethra so that the distal balloon is positioned at the neck of the bladder; inflating the proximal and distal balloons; and providing axial tension along the intermediate portion of the catheter. The axial tension urges the proximal and distal balloons towards one another.
  • Figure 1 is a partial view of the catheter of the present invention located in the drug delivery position within the male urethra and bladder.
  • Figure 2 is a cross section of the catheter shown in Figure 1 taken along line 2-
  • FIG. 3 is a cross section of the catheter shown in Figure 1 taken along line 3-
  • Figure 4 is a partial view of the catheter illustrated in Figure 1 showing a pear- shaped distal occlusion balloon.
  • Figure 5 is a cross section of the pear-shaped distal occlusion balloon illustrated in Figure 4 taken along line 5-5.
  • Figure 6 is a partial view of the catheter illustrated in Figure 1 showing a distal occlusion balloon having a conical end portion.
  • Figure 7 is a partial view of the catheter illustrated in Figure 1 showing a cross- sectional view of a toroidal-shaped distal occlusion balloon.
  • Figure 8 is a partial cross section of the catheter illustrated in Figure 1 having an electrode.
  • the present invention comprises a catheter with two balloons for isolating a target area for treatment.
  • a portion of the catheter between the two balloons is elastic, which enhances the sealing effect of the balloons.
  • the catheter is capable of delivering fluid to the target area of the passageway that is isolated between the balloons.
  • the present invention can be used to deliver fluid to the prostate gland and is advantageous in that the prostatic ducts remain substantially open, even when the balloons are inflated.
  • the present invention is described in terms of a urinary catheter for treating a patient's prostate gland, one skilled in the art will realize that the present invention can be used with other types of catheters.
  • the present invention could be used with a cardio-vascular catheter; a catheter configured to treat a patient's windpipe; an endoscope, which is a form of catheter; or the like.
  • FIG. 1 illustrates one possible embodiment of a catheter according to the present invention, generally shown as 20, for isolating a segment of the urethra 22 and treating a prostate gland 24.
  • the urethra 22 includes the prostatic urethra 26, a membranous urethra 28, and a bulbous urethra 30.
  • the prostatic urethra 26 is that portion of the urethra 22 that passes though the prostate gland 24.
  • the present invention includes a catheter body 32 having a proximal or first portion 34, an intermediate or second portion 36, and a distal or third portion 38.
  • the proximal and distal portion 34 and 36 have a first outer diameter that is substantially uniform.
  • a proximal occlusion balloon 40 and a distal occlusion balloon 42 are operably connected to catheter body 32 proximate oppositely disposed ends of intermediate portion 36.
  • the distance between the proximal occlusion balloon 40 and the distal occlusion balloon 42 is approximately equal to the combined length of the average prostatic urethra 26 and the average membranous urethra 28.
  • Proximal and distal occlusion balloons 40 and 42 can be made from either elastic material or inelastic material.
  • suitable elastic materials include latex, polyurethane, or silicon.
  • suitable inelastic materials include polyethylene, polycarbonate, or PET.
  • Figure 2 illustrates a cross-section of the proximal portion 34 of catheter body 32.
  • Figure 3 illustrates a cross-section of the intermediate portion 36 of the catheter body 32.
  • catheter body 32 defines a delivery lumen 44 having a substantially uniform diameter and a first inflation lumen 46 having a substantially uniform diameter.
  • Delivery ports 48 extend between the delivery lumen 44 and the surface of the catheter body 32 at a point between the distal and proximal occlusion balloons 40 and 42.
  • the first inflation lumen 46 is in fluid communication with distal occlusion balloon 42 via a first inflation port (not shown).
  • a second inflation lumen 50 is in fluid communication with proximal occlusion balloon 40 via a second inflation port (not shown).
  • a drainage lumen 51 extends through catheter body 32 and opens at distal end 52.
  • the second inflation lumen 50 terminates proximal to the proximal occlusion balloon 40 and thus does not extend through the intermediate portion 36 of the catheter body 32.
  • a cross-section of proximal portion 34 of catheter body 32 has a greater area than the cross-section of intermediate portion 36 of catheter body 32.
  • the intermediate portion 36 has more elasticity than proximal portion 34.
  • the distal portion 38 of the catheter body 32 has a cross- sectional area similar to that of the proximal portion 34, which is represented in Figure 2.
  • a part of the intermediate portion 36 can have a greater cross-sectional area as shown in Figure 2, so long as there is a segment of the intermediate portion 36 that has a smaller cross-sectional area so that elasticity is increased enough to permit the caregiver to generate axial tension between the proximal and distal occlusion balloons 40 and 42.
  • proximal and distal occlusion balloons 40 and 42 are preferably mounted on the catheter body 32 in a position that has the larger cross-sectional area shown in Figure 2. This positioning will ensure that the axial tension is concentrated between the proximal and distal occlusion balloons 40 and 42.
  • the catheter 20 can be made from two different materials having different elasticity.
  • the distal and proximal portions 34 and 38 of the catheter 20 might be formed from one material having a predetermined elasticity.
  • the intermediate portion 36 then can be formed from a second material that has predete ⁇ nined elasticity greater than the elasticity of the material that forms the proximal and distal portions 34 and 38 of the catheter body 32.
  • the intermediate portion 36 can be spliced between the proximal and distal portions using a variety of manufacturing techniques that are well known in the art.
  • the proximal, intermediate, and distal portions 34, 36, and 38 can have the same cross-sectional area.
  • catheter 20 is inserted into the urethra 22 using lubrication, sterile techniques, or any other technique that is commonly used to insert a Foley-type urological catheter.
  • Catheter 20 is inserted into the urethra 22 until the distal occlusion balloon 42 enters the bladder 54 and is preferably inserted while there is urine within the bladder 54. Having urine within the bladder 54 is useful because the caregiver who inserts the catheter 20 will know that the distal occlusion balloon 42 has entered the bladder 54 when urine is observed in the drainage lumen 51 or when urine can be aspirated through the drainage lumen 51.
  • distal occlusion balloon 42 Once the distal occlusion balloon 42 is inserted within the bladder 54, fluid is injected through first inflation lumen 46 until the distal occlusion balloon 42 is inflated to a diameter in the range of about 2 cm to about 4 cm. After distal occlusion balloon 42 is inflated, the caregiver pulls on the proximal portion 34 of the catheter body 32, which causes the intermediate portion 36 to expand, thereby generating axial tension. The proximal occlusion balloon 40 should be positioned in the bulbous urethra 30. The caregiver can then inflate the proximal occlusion balloon 40 and release the proximal portion 34 of the catheter body 32.
  • intermediate portion 36 causes axial tension that urges the distal and proximal occlusion balloons 40 and 42 to move toward one another.
  • the axial tension seats the proximal occlusion balloon 40 against the narrowing wall of the bulbous urethra 30, which enhances its sealing effect.
  • the combination of pulling on the proximal portion 34 of the catheter body 32 and the resulting axial tension seats the distal occlusion balloon 42 at the bladder neck 56 and enhances its sealing effect.
  • the caregiver can use a predetermined, fixed volume of fluid in order to prevent over inflation and bursting of the balloons 40 and 42.
  • the fluid can be air, water, or saline, etc. However, the preferred fluid is sterile water.
  • distal occlusion balloon 42 When the catheter 20 in a delivery position, the distal occlusion balloon 42 is positioned so that it is primarily located in the bladder neck 56. However, a portion of distal occlusion balloon 42 may be located within the portion of the prostatic urethra 26 closest to the bladder neck 56. The reason is that substantially all of the prostatic ducts open in the proximal three quarters of the prostatic urethra 26. Consequently, positioning distal occlusion balloon 42 in this manner causes a minimal amount, if any, of the prostatic ducts to seal shut when the catheter 20 is in the delivery position.
  • Drugs or diagnostic fluids may be delivered to the prostate gland 24 after catheter 20 is in the delivery position and the proximal and distal occlusion balloons 40 and 42 are inflated.
  • a pressure gauge and syringe can be placed in fluid communication with delivery lumen 44 to deliver the drug or diagnostic fluid to the prostatic urethra 26.
  • Any number of types of syringes may be used such as a standard syringe, an adjustable syringe, or a syringe pump. However, an adjustable syringe is preferably used.
  • An adjustable syringe is one that has threads or some other type of self-locking mechanism.
  • the drug or diagnostic fluid is pressurized, thereby transporting it into the ducts, ductules, and acini.
  • the pressure on the fluid may range between from about 0.1 psi to about 10 psi. However, the preferable pressure is between about 0.1 psi and about 6 psi. The most preferred range of pressure is between about 0.1 psi and about 5 psi. This pressure causes the fluid to fill the prostatic ducts, ductules, and acini.
  • a constant pressure should be maintained over a period of time ranging from about 0.1 hours to about 4 hours. The preferred range of time is between about 0.1 hours to about 2 hours, and the most preferred range is between about 0.1 hours and about 0.5 hours.
  • the precise amount of time will vary depending on the drug or the diagnostic agent being employed.
  • the preferable procedure for withdrawing catheter 20 from the urethra 22 depends on whether toxic or caustic agents were delivered. For nontoxic drugs and diagnostic fluids such as antibiotics, anti-inflammatories, and positive contrast agents, the pressure of the fluid is simply reduced to zero. The distal and proximal occlusion balloons 40 and 42 are then deflated, and catheter 20 is removed from the urethra 22.
  • an alternative procedure for withdrawing catheter 20 is preferred. More specifically, a slight negative pressure is applied to the fluid in order to remove the excess drug or diagnostic agent from the urethra 22 after the administration period is complete.
  • the urethra 22 may then be flushed with a saline solution.
  • the saline solution is added and removed via the delivery lumen 44 in the same fashion the drug or diagnostic fluid was initially delivered to the prostatic urethra 26. After the saline solution is removed, distal and proximal occlusion balloons 40 and 42 are deflated and catheter 20 is removed.
  • the distance between the proximal and distal occlusion balloons 40 and 42 can be about the same length as or slightly longer than the average prostatic urethra 26.
  • the proximal occlusion balloon 40 will be located in the membranous urethra 28 when the catheter 20 is in the delivery position, so that the proximal occlusion balloon 40 will exert minimal pressure against the wall of the prostatic urethra 26.
  • a rmnimal number of prostatic ducts will collapse when catheter 20 is in the drug delivery position.
  • the caregiver should inflate the distal occlusion balloon 42 and then pull on the proximal portion 34 of the catheter body 32 which will generate axial tension along the intermediate portion 36.
  • the caregiver can maintain the axial tension by taping or clamping the proximal portion 34 of the catheter body 32 to the patient's body. This action will ensure that the distal occlusion balloon 42 remains seated and sealed at the bladder neck 56.
  • the caregiver should then inflate the proximal occlusion balloon 40.
  • the pressure of the inflation fluid will seal the proximal occlusion balloon 40 against the wall of the membranous urethra 28.
  • This alternative embodiment is advantageous when delivering toxic or otherwise harmful drugs that could harm the patient if exposed to tissue other than the prostate gland 24.
  • a possible range of distance between the proximal and distal occlusion balloons 40 and 42 is from about 3 cm to about 7 cm. If the proximal occlusion balloon 40 is to be located in the membranous urethra 28 when the catheter 20 is in the delivery position, a possible range of distance between the proximal and distal occlusion balloons 40 and 42 in this embodiment is from about 3 cm to about 6 cm.
  • the distance between the proximal and distal occlusion balloons 40 and 42 can vary depending on the length of the patient's urethra 22.
  • the caregiver may have several catheters 20 available, each having different distances between the proximal and distal occlusion balloons 40 and 42.
  • the catheter 20 may have a telescoping body (not shown) in which the proximal occlusion balloon 40 is attached to a tubular, outer portion and the distal occlusion balloon 42 is attached to an extendable, inner portion.
  • a hemostatic-type adjustable seal can be used to secure the extendable portion relative to the tubular portion.
  • a telescoping catheter body An advantage of a telescoping catheter body is that the distance between the proximal occlusion balloon 30 and the elongating balloon 28 can be adjusted to the length of the patient's urethra 15. Additionally, the relative position of the proximal occlusion balloon 30 can be adjusted so that it is positioned in either the membranous urethra 18 or the bulbous urethra 19 when the catheter 20 is in the delivery position. Additionally, a telescoping catheter can be used in an alternative method of creating axial tension.
  • the caregiver can insert the catheter 20 through the patient's urethra so that the distal occlusion balloon 42 is located in the bladder 54 and the proximal occlusion balloon 40 is located in the bulbous urethra 30.
  • the caregiver also inflates the proximal occlusion balloon 40 and the distal occlusion balloon 42.
  • the caregiver can slide the tubular portion along the extendible portion, thereby causing proximal and distal occlusion balloons 40 and 42 to move toward one until the proximal occlusion balloon 40 becomes seated against the wall of the bulbous urethra 30 and the distal occlusion balloon 42 becomes seated at the bladder neck 56.
  • the caregiver can initially position and then inflate the proximal occlusion balloon 40. Once the proximal occlusion balloon 40 is positioned, the caregiver can secure the tubular portion to the patient's body using tape or a clamping device. The distal occlusion balloon 42 is inflated. The caregiver then retracts the extendable portion until the distal occlusion balloon 42 is seated at the bladder neck 56 and there is a sufficient amount of axial tension between the proximal and distal occlusions 40 and 42.
  • This alternative method of using a telescoping catheter is useful when the proximal occlusion balloon 40 is to be positioned in the membranous urethra 28 during delivery.
  • the distal occlusion balloon 42 can have a variety of configurations such as pear-shape, a balloon with a conical portion, a toroid shape, or other configurations.
  • Figure 4 illustrates a first alternative embodiment in which a pear-shaped balloon 58, shown in an inflated state, serves as a unitary positioning balloon and distal occlusion balloon.
  • the pear-shaped balloon 58 has a proximal portion 60 that is configured for isolating the prostatic urethra 26 and a distal portion 62 that is configured for locating the catheter 20 in the delivery position.
  • Figure 5 shows a cross-sectional view of the pear-shaped balloon 58 in a deflated state.
  • the pear-shaped balloon 58 When in the deflated state, the pear-shaped balloon 58 has a substantially uniform outer diameter. The thickness of the balloon wall at the proximal portion 60 is greater than the thickness of the wall at the distal portion 62. As a result, a chamber 64 defined by the pear-shaped balloon 58 has a smaller inner diameter at the proximal portion 60 than the distal portion 62.
  • the proximal portion 60 is sized to be placed into sealing engagement with the bladder neck 56.
  • the proximal portion 60 can be sized to partially extend into the portion of the prostatic urethra 26 that is adjacent to the bladder neck 56.
  • the distal portion 62 is wider than the proximal portion 60 and is configured to become seated at the bladder neck 56 and locate the catheter 20 in the delivery position when the caregiver initially pulls on the proximal portion 34 of the catheter body 32 as described above.
  • Pear-shaped balloons are described in more detail in United States Patent 5,419,763, the disclosure of which was incorporated by reference above.
  • Figure 6 illustrates another alternative embodiment in which a distal occlusion balloon 65 has a proximal end 66 and a distal end 68.
  • Proximal and distal ends 66 and 68 have a conical configuration.
  • proximal end 66 fits snugly in the bladder neck 56 and creates a seal when distal occlusion balloon 65 is in an inflated state.
  • This seal substantially isolates the prostatic urethra 26 from the bladder neck 56 and bladder 54.
  • the use of balloons such as distal occlusion balloon 65 or pear-shaped balloon 58 are advantageous when delivering toxic or dangerous agents that may cause unwanted side effects or harm if exposed to tissue other than the prostate gland 24.
  • Figure 7 illustrates yet another alternative embodiment in which a toroid- shaped balloon 70 serves as the distal occlusion balloon.
  • the toroid-shaped balloon 70 When in an inflated state, the toroid-shaped balloon 70 has a proximal end 72, that has an arcuate shape and is convex. In other words, the proximal end 72 bulges outward.
  • the proximal end 72 creates a seal against the wall of the bladder 54.
  • the bladder neck 56 remains in fluid communication with the prostatic urethra 26.
  • the bladder 54 is substantially isolated from both the bladder neck 56 and the prostatic urethra 26.
  • Using the toroid-shaped balloon 70 is advantageous when anesthetizing a patient before prostatic surgery. The anesthesia helps numb nerves at the bladder neck 56, which can become irritated during surgery.
  • the catheter 20 can utilize iontophoresis, electroporation, and/or phonophoresis to assist the transportation of the agent into the prostatic ducts.
  • non-pressure means of transportation also enhance drug penetration across the prostatic epithelium and into prostatic tissue. These methods may also increase cellular penetration of certain agents. Examples of these agents include DNA, RNA, etc. These non-pressure means of transportation may also make penetration into prostatic calculi possible. Iontophoresis, electroporation, and phonophoresis are discussed in more detail in United States Patent 5,419,763, the disclosure of which was incorporated by reference above. Additional information on iontophoresis can be found in United States Application Serial No. 07/705,731, which was filed on May 24, 1991 ; United States Application Serial No. 07/957,209, which was filed on October 6, 1992; and United States Patent 5,286,254, the disclosures of which are hereby incorporated by reference.
  • the catheter 20 can include a sheath 74 that covers an electrode 76 and delivery ports 48.
  • the sheath 74 can be tubular and fixed to the catheter body 32 with adhesive 78.
  • the sheath 74 can be formed from a polymer matrix that absorbs fluid that passes through the delivery ports 48.
  • the sheath 74 can be formed from a porous membrane.
  • the pores can be either microporous (0.2-100 micron) or macroporous (100 micron-1 millimeter) depending on the density of the pores and manufacturing process.
  • the catheter body 32 can include a portion 80 that has a narrowed diameter, thereby defining a recess 82.
  • narrow portion 80 can correspond to intermediate portion 36.
  • the electrode 76 is positioned within the recess 82.
  • the sheath 74 extends over the recess 82 and forms a delivery chamber 84 that is in fluid communication with delivery ports 48. In use, the fluid fills delivery chamber 84 and is either absorbed in sheath 74 or passes through the pores defined in sheath 74, thereby forming a path between the electrode 76 and the patient's body that is capable of conducting an electric current.
  • the electrode 76 can be mounted on the proximal or distal portion 34 or 38 of the catheter body, which has a larger diameter. In this alternative embodiment, the electrode 76 is still positioned between the distal and proximal occlusion balloons 40 and 42. Additionally, if sheath 74 is absorbent, catheter body 32 may define only a single delivery port 48 positioned proximate to one of the sheath's 74 oppositely disposed ends 86 or 88.
  • the sheath 74 has several advantages. For example, the sheath 74 will prevent the electrode 76 from being placed in direct contact with tissue along the urethral wall. Additionally, the sheath 74 helps to distribute the current so that there is not a single point at which the current will pass from the electrode 76 to the tissue. As a result, hot spots are prevented, which might otherwise cause the tissue directly adjacent to the electrode 76 to burn.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention concerne un appareil servant à amener un fluide à une zone de traitement d'un patient. L'appareil comprend un cathéter (32) ayant une première partie (34), une deuxième partie (36) et une troisième partie (38). La deuxième partie (36) est plus élastique que les deux autres et est placée entre elles. Un ballon proximal (40) est relié à la première partie de manière opérationnelle. Un ballon distal (42) est relié à la troisième partie de manière opérationnelle. La première partie a une première superficie en section transversale, la seconde partie a une seconde superficie en section transversale et la troisième partie a une troisième superficie en section transversale. La première superficie en section transversale et la troisième superficie en section transversale sont plus grandes que la deuxième superficie en section transversale.
PCT/US1997/004614 1996-03-29 1997-03-21 Catheter et procede pour provoquer une tension le long de l'axe du catheter WO1997036632A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62625396A 1996-03-29 1996-03-29
US08/626,253 1996-03-29

Publications (1)

Publication Number Publication Date
WO1997036632A1 true WO1997036632A1 (fr) 1997-10-09

Family

ID=24509595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004614 WO1997036632A1 (fr) 1996-03-29 1997-03-21 Catheter et procede pour provoquer une tension le long de l'axe du catheter

Country Status (1)

Country Link
WO (1) WO1997036632A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041743A1 (fr) * 1999-01-12 2000-07-20 Michelina Tricarico Dispositif pour drainer une substance exsudative d'une cavite intracorporelle d'un patient
WO2001083018A1 (fr) * 2000-05-04 2001-11-08 University Of Brighton Dispositif de distribution de fluide
WO2007111736A1 (fr) * 2006-03-27 2007-10-04 Boston Scientific Scimed, Inc. dispositifs médicaux aux capacités d'administration locale de médicament
EP1854497A1 (fr) * 2005-03-04 2007-11-14 Olympus Medical Systems Corp. Dilatateur a ballon
WO2017161331A1 (fr) 2016-03-18 2017-09-21 Procept Biorobotics Corporation Procédés et systèmes très peu invasifs pour l'hémostase d'un volume tissulaire hémorragique clos
US10736689B2 (en) 2008-08-20 2020-08-11 Prostacare Pty Ltd Low-corrosion electrode for treating tissue
US11224474B2 (en) 2018-02-28 2022-01-18 Prostacare Pty Ltd System for managing high impedance changes in a non-thermal ablation system for BPH
US11457975B2 (en) 2017-11-27 2022-10-04 Prostacare Pty Ltd Apparatus and a method for the treatment of a prostatic disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784651A (en) * 1985-03-14 1988-11-15 The Victoria University Of Manchester Urethral catheter
EP0402467A1 (fr) * 1988-02-15 1990-12-19 Terumo Kabushiki Kaisha Tube de catheter et endoscope
US5104377A (en) * 1989-08-10 1992-04-14 C. R. Bard, Inc. Uterine access device with automatic cervical adjustment
US5419763A (en) * 1994-01-04 1995-05-30 Cortrak Medical, Inc. Prostatic drug-delivery catheter
US5462529A (en) * 1993-09-29 1995-10-31 Technology Development Center Adjustable treatment chamber catheter
US5478309A (en) * 1994-05-27 1995-12-26 William P. Sweezer, Jr. Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery
EP0697205A1 (fr) * 1994-08-17 1996-02-21 Roewer, Norbert, Dr. Sonde gastrique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784651A (en) * 1985-03-14 1988-11-15 The Victoria University Of Manchester Urethral catheter
EP0402467A1 (fr) * 1988-02-15 1990-12-19 Terumo Kabushiki Kaisha Tube de catheter et endoscope
US5104377A (en) * 1989-08-10 1992-04-14 C. R. Bard, Inc. Uterine access device with automatic cervical adjustment
US5462529A (en) * 1993-09-29 1995-10-31 Technology Development Center Adjustable treatment chamber catheter
US5419763A (en) * 1994-01-04 1995-05-30 Cortrak Medical, Inc. Prostatic drug-delivery catheter
US5419763B1 (en) * 1994-01-04 1997-07-15 Cor Trak Medical Inc Prostatic drug-delivery catheter
US5478309A (en) * 1994-05-27 1995-12-26 William P. Sweezer, Jr. Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery
EP0697205A1 (fr) * 1994-08-17 1996-02-21 Roewer, Norbert, Dr. Sonde gastrique

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041743A1 (fr) * 1999-01-12 2000-07-20 Michelina Tricarico Dispositif pour drainer une substance exsudative d'une cavite intracorporelle d'un patient
WO2001083018A1 (fr) * 2000-05-04 2001-11-08 University Of Brighton Dispositif de distribution de fluide
EP1854497A1 (fr) * 2005-03-04 2007-11-14 Olympus Medical Systems Corp. Dilatateur a ballon
EP1854497A4 (fr) * 2005-03-04 2010-08-04 Olympus Medical Systems Corp Dilatateur a ballon
WO2007111736A1 (fr) * 2006-03-27 2007-10-04 Boston Scientific Scimed, Inc. dispositifs médicaux aux capacités d'administration locale de médicament
US10736689B2 (en) 2008-08-20 2020-08-11 Prostacare Pty Ltd Low-corrosion electrode for treating tissue
US10842555B2 (en) 2008-08-20 2020-11-24 Prostacare Pty Ltd Catheter for treating tissue with non-thermal ablation
US10939957B2 (en) 2008-08-20 2021-03-09 Prostacare Pty Ltd Non-thermal ablation system for treating tissue
CN109152650A (zh) * 2016-03-18 2019-01-04 普罗赛普特生物机器人公司 用于在出血的闭合组织体积中止血的微创方法和***
EP3429513A4 (fr) * 2016-03-18 2020-03-18 Procept Biorobotics Corporation Procédés et systèmes très peu invasifs pour l'hémostase d'un volume tissulaire hémorragique clos
WO2017161331A1 (fr) 2016-03-18 2017-09-21 Procept Biorobotics Corporation Procédés et systèmes très peu invasifs pour l'hémostase d'un volume tissulaire hémorragique clos
CN109152650B (zh) * 2016-03-18 2021-10-26 普罗赛普特生物机器人公司 用于在出血的闭合组织体积中止血的微创方法和***
US11278293B2 (en) 2016-03-18 2022-03-22 Procept Biorobotics Corporation Minimally invasive methods for hemostasis in a bleeding closed tissue volume without occlusion
US11553924B2 (en) 2016-03-18 2023-01-17 Procept Biorobotics Corporation Minimally invasive systems with expandable supports for hemostasis in a bleeding closed tissue volume
US11871933B2 (en) 2016-03-18 2024-01-16 Procept Biorobotics Corporation Tensioning apparatus for hemostasis and maintaining catheter placement
US11457975B2 (en) 2017-11-27 2022-10-04 Prostacare Pty Ltd Apparatus and a method for the treatment of a prostatic disease
US11224474B2 (en) 2018-02-28 2022-01-18 Prostacare Pty Ltd System for managing high impedance changes in a non-thermal ablation system for BPH

Similar Documents

Publication Publication Date Title
US5419763A (en) Prostatic drug-delivery catheter
US4655746A (en) Catheter device
CA1315633C (fr) Catheter a ballon pour perfusion
JP4808356B2 (ja) 小型弁
EP1005382B1 (fr) Catheter a ballonnet
US5688237A (en) Implantable catheter and method of use
EP1330285B1 (fr) Dispositif et procede d'administration d'un anesthesique local applique de maniere topique sur une paroi formant un passage dans des tissus
US7621895B2 (en) Needle array devices and methods
EP1351738B1 (fr) Catheter d'administration de medicaments muni d'un ballonnet tres elastique perce de trous de perfusion
CA2467406C (fr) Ensemble catheter d'administration de medicament a ballonnet gonflable
JPH05245210A (ja) カテーテルと導入部材との組立体
KR20140067012A (ko) 신체 내로 치료제를 주입하기 위한 조립체, 시스템, 및 방법
JPH07500523A (ja) ポリマー・マトリックス薬剤配給装置および方法
US20200171285A1 (en) Dual double balloon catheter
US5713861A (en) Trauma urethral catheter and method of using same
JP2006271831A (ja) 医療用治療装置およびその装置の使用方法
WO1997036632A1 (fr) Catheter et procede pour provoquer une tension le long de l'axe du catheter
JPH04261668A (ja) カテーテルチューブ
WO1997036630A1 (fr) Catheter urinaire
WO1997036631A1 (fr) Catheter urinaire dont un ballon s'allonge
WO2001017589A1 (fr) Catheter multicanules pour l'administration d'une therapie en divers points d'un vaisseau, dans lequel le flot de fluide au-dela du catheter est arrete
JPH0337078A (ja) カテーテルコネクタおよびカテーテル組立体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97535329

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase